Uncategorized
Replicor to present data on beneficial effects of transaminase flares on HBV functional cure at 2019 EASL AASLD Endpoints Meeting
MONTREAL, March 1st, 2019 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced it will present data indicating the beneficial impact of transaminase flares during therapy on achieving HBV functional cure at the 2019 EASL / AASLD HBV Endpoints Meeting to be held March…
Read MoreReplicor announces publication of new study examining antiviral mechanisms of REP 2139
MONTREAL, February 18th, 2019 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces the publication of new data examining the antiviral mechanism of REP 2139 in HBV infection in the journal of Antiviral Research. https://www.sciencedirect.com/science/article/pii/S0166354218307551?via%3Dihub The…
Read MoreReplicor to update analysis of high rates of functional cure of HBV at APASL 2019
Replicor to update analysis of high rates of functional cure of HBV at APASL 2019 MONTREAL, February 11, 2019 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced it will present analysis of its HBV functional cure data from the ongoing REP 401 study at…
Read MoreReplicor announces publication of new study validating HBsAg responses driven by REP 2139
MONTREAL, November 21st, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces the publication of new data validating the clearance of HBsAg in response to NAP therapy in the Journal of Viral Hepatitis (https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13044). The…
Read MoreReplicor to disclose achievement of high rates of functional cure of HBV at AASLD 2018
MONTREAL, November 6, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced its presentation of the latest follow-up data from its ongoing REP 401 study at the 2018 meeting of the American Association for the Study of Liver Disease (AASLD) to be held November…
Read MoreReplicor showcases HBV functional cure data with REP 2139-Mg
MONTREAL, October 15, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, presented updated clinical data showing achievement of functional cure of HBV and HDV infections with REP 2139-based combination therapy at the “Antivirals: Targeting HBV…
Read MoreReplicor publishes updated review of REP 2139 and its application in treating HBV and HDV
MONTREAL, September 17th, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces the publication of an updated invited review article on REP 2139 in the journal ACS Infectious Diseases (https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.8b00156). This updated review of REP…
Read MoreReplicor demonstrates high rates of persistent functional control of HBV infection following cessation of all therapy
MONTREAL, June 18, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, presented updated mechanistic and clinical data last week at the Global Hepatitis Summit 2018 (16th International Symposium on Viral Hepatitis and Liver Disease) held June…
Read MoreReplicor updates mechanistic and clinical data demonstrating high rates of functional control of HBV and HDV infection at The Science of HBV Cure 2018
MONTREAL, June 11, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, presented updated mechanistic and clinical data last week at the Science of HBV Cure workshop, a part of the Singapore Hepatology Conference, held June…
Read MoreReplicor discloses long term functional control of HBV and HDV infection in high proportions of treated patients at EASL 2018
MONTREAL, April 13, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, presented today the evolving long-term follow-up data from its REP 301-LTF and REP 401 studies at the 2018 International Liver Conference of the European…
Read More